Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Breast 2

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Ovarian Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma in Situ 1

Interventions

Paclitaxel 143pembrolizumab 121Carboplatin 109Bevacizumab 93Cisplatin 69Specimen Handling 62olaparib 51Magnetic Resonance Spectroscopy 51Gemcitabine 41Nivolumab 36Biopsy 36liposomal doxorubicin 34Taxes 33Cyclophosphamide 31Blood Specimen Collection 31niraparib 28lenvatinib 26Letrozole 26Doxorubicin 26Topotecan 25Drug Therapy 25Immunoglobulin G 23Brachytherapy 22fludarabine 21atezolizumab 21Radiotherapy 21Disulfides 21durvalumab 20dostarlimab 19Surveys and Questionnaires 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Indomethacin × Gynecologic × 1 year × Clear all
NCT01719926 2026-06-04

PIFA

UMC Utrecht

Phase 1 Completed
13 enrolled
GastrointestinalGynecologic

Esophageal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡